FallExam2Drugs.txt

Card Set Information

Author:
Anonymous
ID:
102939
Filename:
FallExam2Drugs.txt
Updated:
2011-09-19 22:47:11
Tags:
FallExam2Drugs
Folders:

Description:
Calcium Homeostasis
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user Anonymous on FreezingBlue Flashcards. What would you like to do?


  1. Teriparatide Acetate
    • Synthetic PTH which in
    • Bone- increases ca2+ mobilization
    • Kidney- increases Ca2+ and Mg2+ reabsorption, decreases phosphate reabsorption, increases Vit D production
    • Intestine- increases Ca2+ absorption cause of Vit. D being produced in Kidney
    • Uses: Osteoporosis if given intermittently, Hypoparathyroidism, Diagnoses pseudohypoparathyroidism (increase in cAMP after challenge denotes normal PTH responsiveness).
    • Adverse Effects: NOT USED FOR HYPOCALCEMIA!!!!, Hyperparathyroidism, May increase risk of osteomalacia so do not use in patients with other bone issues
  2. Calcitonin
    • Human CT or synthetic salmon CT with longer halflife decreases serum Ca2+ by decreasing osteoclast activity and increasing Ca2+ excretion
    • Use: OSteoporosis, Paget's disease, Hypercalcemia
    • Adverse Effects: nausea, facial flushing, swelling of hands, inflammatory reactions at injection sites, urticaria (rash), salmon form shows hypersensitivity or resistance.
  3. Etidronate
    • Biphosphonates (pyrophosphate analog)
    • Uses: Osteoporosis, Paget's disease, Hypercalcemia associated with malignancy, Given during Glucocorticoid therapy to prevent bone mineral loss
    • MOA: Binds hydroxyapatite in bone and incapacitates osteoclast breakdown;
    • Adverse Effects: Upper GI distress (sit upright 30 min after dose), Hypocalcemia, Hypophosphatemia, Poorly absorbed cus oral bioavailability very low
  4. Alendronate
    • Biphosphonates (pyrophosphate analog)
    • Uses: Osteoporosis, Paget's disease, Hypercalcemia associated with malignancy, Given during Glucocorticoid therapy to prevent bone mineral loss
    • MOA: Binds hydroxyapatite in bone and incapacitates osteoclast breakdown;
    • Adverse Effects: Upper GI distress (sit upright 30 min after dose), Hypocalcemia, Hypophosphatemia, Poorly absorbed cus oral bioavailability very low
  5. Risedronate
    • Biphosphonates (pyrophosphate analog)
    • Uses: Osteoporosis, Paget's disease, Hypercalcemia associated with malignancy, Given during Glucocorticoid therapy to prevent bone mineral loss
    • MOA: Binds hydroxyapatite in bone and incapacitates osteoclast breakdown;
    • Adverse Effects: Upper GI distress (sit upright 30 min after dose), Hypocalcemia, Hypophosphatemia, Poorly absorbed cus oral bioavailability very low
  6. Denosumab
    • human anti-RANK ligand monoclonal antibody
    • Uses: Osteoporosis in postmenopausal women
    • MOA: binds RANKL and inhibits maturation of preosteoclasts, decreases bone remodeling, increases bone mineral density
    • Adverse Effects: Hypocalcemia, infections, skin reactions, osteonecrosis of jaw, contraindicated in hypocalcemia
  7. Vitamin D (Calcitrol)
    • Vitamin D increases calbindin surface protein to increase intestinal absorption of Ca2+, synthesises bone matrix osteocalcin, enhances osteoclast formation and ca2+ mobilization; Stored in fate
    • Use: Rickets, Osteomalacia, Osteoporosis, Hypoparathyroidism, Pseudohypoparathyroidism
    • Adverse Effects: Hypervitaminosis D and Hypercalcemia (treat with fluid support, withdraw Vit D from diet, and glucocorticoids)

What would you like to do?

Home > Flashcards > Print Preview